Kerendia: What Changes for Type 1 Diabetic Kidney

What does Kerendia's FDA approval mean for type 1 diabetes?

The September approval extends finerenone, sold as Kerendia, to another diabetes population. Its indication specifically addresses urinary albumin-to-creatinine ratio, or UACR, a measurement of protein leaking into urine. The FDA label states that lowering this marker is expected to reduce sustained loss of kidney filtration and progression to end-stage kidney disease. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215341s011lbl.pdf)

Finerenone blocks mineralocorticoid receptors, whose excessive activation contributes to harmful processes in the kidneys and heart. This oral medicine adds another approach to kidney care alongside established diabetes treatment. Bayer's approval announcement explains that the decision connects the new type 1 diabetes findings with earlier trials linking reduced albuminuria to better kidney outcomes in type 2 diabetes. [Bayer approval announcement](https://www.bayer.com/en-us/united-states/news-and-stories/2026/treatment-forchronic-kidney-disease-and-type-1-diabetes)

How much did finerenone help in the FINE-ONE trial?

FINE-ONE randomly assigned 242 adults with type 1 diabetes, chronic kidney disease and elevated urinary albumin to finerenone or placebo. Participants were already taking an ACE inhibitor or angiotensin receptor blocker. UACR fell by 34% with finerenone and 12% with placebo; the adjusted comparison represented a 25% relative reduction versus placebo. Bayer funded the study, published in the New England Journal of Medicine. [FINE-ONE trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2512854)

The distinction between a laboratory marker and a clinical outcome matters. These findings should not be interpreted as 25% fewer patients needing dialysis. The FDA's assessment used the albuminuria response to infer longer-term protection, supported by kidney outcome trials in type 2 diabetes. Consequently, the expected benefit is meaningful, but its precise size for kidney failure in type 1 diabetes remains uncertain. [FDA assessment in the prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215341s011lbl.pdf)

What safety checks are needed before taking Kerendia?

Elevated potassium, called hyperkalemia, is a central concern. In FINE-ONE, it occurred in 10.1% of finerenone recipients and 3.3% of placebo recipients; two participants stopped finerenone because of it. These findings make laboratory follow-up an essential part of treatment. [FINE-ONE safety results](https://www.nejm.org/doi/full/10.1056/NEJMoa2512854)

For diabetes-associated kidney disease, the prescribing information calls for potassium testing four weeks after starting treatment, four weeks after dose changes and periodically thereafter. Strong CYP3A4 inhibitors cannot be combined with Kerendia, and grapefruit should be avoided. Clinicians also need to review medicines and supplements that could raise potassium before deciding whether treatment is appropriate. [FDA monitoring and interaction guidance](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215341s011lbl.pdf)